Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Jessica K Altman

ECOG-ACRIN Cancer Research Group

Intervention

Azacitidine(drug)

Enrollment

147 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (30)

• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
• Kaiser Permanente Dublin, Dublin, California, United States
• Kaiser Permanente-Fremont, Fremont, California, United States
• Kaiser Permanente Fresno Orchard Plaza, Fresno, California, United States
• Kaiser Permanente-Fresno, Fresno, California, United States
• Cedars Sinai Medical Center, Los Angeles, California, United States
• Kaiser Permanente- Modesto MOB II, Modesto, California, United States
• Kaiser Permanente-Modesto, Modesto, California, United States
• Kaiser Permanente-Oakland, Oakland, California, United States
• Kaiser Permanente-Roseville, Roseville, California, United States
• Kaiser Permanente Downtown Commons, Sacramento, California, United States
• University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06303193
  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
  National Cancer Institute (NCI)
• RECRUITINGNANCT07500753
  A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE3NCT07422480
  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGPHASE4NCT07486713
  Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
  Rigel Pharmaceuticals
• RECRUITINGPHASE1NCT07107126
  Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
  Remedy Plan, Inc.
• RECRUITINGPHASE1NCT07270978
  Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
  University of Virginia
• RECRUITINGNANCT06781099
  Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Hospices Civils de Lyon
• RECRUITINGPHASE2NCT07228273
  Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
  OHSU Knight Cancer Institute

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →